Contractome-AI is a learning engine used by Pharma & Biotech Companies in early Drug Discovery to develop safer drugs. It is an intelligent, online, virtual screen for drug-induced cardiac contractility.

Developing pharmaceuticals that do not show heart toxicity is particularly difficult. This is due to the lack of predictive technologies suitable for early Drug Discovery stage use.

Contractome-AI meets this need by linking a drug’s key chemical and biological assay data to its effect in man, and making this available as a rapid, online, virtual screen. It is a learning engine – the more real-world assay data added, the more predictive it becomes.

Contractome-AI’s combination of novel assay and computational methods improves early detection of heart contractility issues, helping avoid expensive downstream problems.
**Competitive Advantages**
- Compatible with Medicinal Chemistry stage use
- Learning Engine: Predictivity improves with use
- Draws from multiple virtual and real-world data sources
- Online user interface for ease of use
- Secure, online, end-to-end encrypted

**Target Markets**
- Pharmaceutical and Biotechnology Companies
- Safety Pharmacologists
- Drug Discovery Project Leaders
- Computational Chemists
- Europe, US, Japan, China and International Markets

**Status/Traction**
- Prototype Completed & available for online customer demonstration – Contact Us
- Contractome-AI is being developed by InoCardia, Cresset BioMolecular, Coventry University and UCB BioPharma

---

**Road Map**

<table>
<thead>
<tr>
<th>Year</th>
<th>Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>MVP completion as a stand-alone online virtual screening platform</td>
</tr>
<tr>
<td>2021</td>
<td>Launch of integrated screening platform as an InoCardia Cardiovascular Safety Service</td>
</tr>
</tbody>
</table>

**Leveraged Technologies**
- PoC: development of a cellular system to predict cardiac contractility risk in Man. PoC: demonstration that this can be used to rank structurally related ligands, transfer to an AI platform and show ability to predict previously unknown structural features governing contractility risk.

**Contact**

Dr Jeremy Billson
Business Champion & Activity Leader

- e: jeremy.billson@inocardia.com
- t: +44 (0) 7988 563489

InoCardia | The TechnoCentre | Puma Way Coventry | CV1 2TT | United Kingdom

---

**Contractome-AI** is an innovation activity proudly supported by EIT Digital. EIT Digital supports entrepreneurial teams from research and business organisations in launching new startups and new products in agile 12-month projects called innovation activities. These activities are embedded in EIT Digital’s European ecosystem and receive a financial co-investment to package their technology, sign up customers and attract investors.